MEDICAMEN BIOTECH Financial Statement Analysis
|
||
|
The Revenues of MEDICAMEN BIOTECH have decreased by -100.00% YoY .
The Earnings Per Share (EPS) of MEDICAMEN BIOTECH has decreased by -4.51 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
MEDICAMEN BIOTECH Last 5 Annual Financial Results
[BOM: 531146|NSE : MEDICAMEQ]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹115 Cr | ₹11,271,608 Cr | ₹126 Cr | ₹123 Cr | ₹123 Cr |
| Expenses | ₹91 Cr | ₹9,304,488 Cr | ₹106 Cr | ₹105 Cr | ₹105 Cr |
| Operating Profit (Excl OI) | ₹24 Cr | ₹1,967,120 Cr | ₹19 Cr | ₹17 Cr | ₹17 Cr |
| Other Income | ₹1.72 Cr | ₹75,405 Cr | ₹1.94 Cr | ₹3.66 Cr | ₹3.66 Cr |
| Interest | ₹1.94 Cr | ₹151,152 Cr | ₹0.93 Cr | ₹1.38 Cr | ₹1.38 Cr |
| Depreciation | ₹5.77 Cr | ₹251,971 Cr | ₹2.50 Cr | ₹2.21 Cr | ₹2.21 Cr |
| Profit Before Tax | ₹18 Cr | ₹1,639,401 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr |
| Profit After Tax | ₹15 Cr | ₹1,212,944 Cr | ₹13 Cr | ₹12 Cr | ₹12 Cr |
| Consolidated Net Profit | ₹15 Cr | ₹1,212,944 Cr | ₹13 Cr | ₹12 Cr | ₹12 Cr |
| Earnings Per Share (Rs) | ₹11.64 | ₹12.19 | ₹9.93 | ₹10.88 | ₹10.28 |
| PAT Margin (%) | 10.46 | 12.90 | 10.76 | 10.59 | 9.81 |
| ROE(%) | 9.06 | 11.25 | 9.89 | 12.94 | 13.95 |
| ROCE(%) | 10.86 | 12.94 | 12.99 | 16.54 | 19.30 |
| Total Debt/Equity(x) | 0.14 | 0.19 | 0.15 | 0.10 | 0.14 |
Key Financials |
||
| Market Cap | : | ₹ 529.3 Cr |
| Revenue (TTM) | : | ₹ 170.7 Cr |
| Net Profit(TTM) | : | ₹ 11.2 Cr |
| EPS (TTM) | : | ₹ 8.8 |
| P/E (TTM) | : | 47.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MEDICAMEN BIOTECH | 1.7% | -21.3% | -34% |
| SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
| CIPLA | 2.5% | 0.4% | 71.7% |
| DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
| ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
| DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
| MANKIND PHARMA | NA | NA | NA |
| TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
| LUPIN | 2.8% | 0% | 147.8% |
MEDICAMEN BIOTECH Revenues
[BOM: 531146|NSE : MEDICAMEQ]
| Y-o-Y | -100.00 % |
| 5 Yr CAGR | -1.49 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹115 Cr | -100.00 | |
| Mar2022 | ₹11,271,608 Cr | 8,980,974.92 | |
| Mar2021 | ₹126 Cr | 2.37 | |
| Mar2020 | ₹123 Cr | 0.00 | |
| Mar2019 | ₹123 Cr | - | |
MEDICAMEN BIOTECH Operating Profit
[BOM: 531146|NSE : MEDICAMEQ]
| Y-o-Y | -100.00 % |
| 5 Yr CAGR | 8.38 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹24 Cr | -100.00 | |
| Mar2022 | ₹1,967,120 Cr | 10,102,201.61 | |
| Mar2021 | ₹19 Cr | 11.52 | |
| Mar2020 | ₹17 Cr | 0.00 | |
| Mar2019 | ₹17 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 19.54 % |
| 5 Yr CAGR | 10.01 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 20.86% | 19.54 | |
| Mar2022 | 17.45% | 12.44 | |
| Mar2021 | 15.52% | 8.99 | |
| Mar2020 | 14.24% | 0.00 | |
| Mar2019 | 14.24% | - | |
MEDICAMEN BIOTECH Profit After Tax
[BOM: 531146|NSE : MEDICAMEQ]
| Y-o-Y | -100.00 % |
| 5 Yr CAGR | 5.50 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹15 Cr | -100.00 | |
| Mar2022 | ₹1,212,944 Cr | 9,125,955.15 | |
| Mar2021 | ₹13 Cr | 10.52 | |
| Mar2020 | ₹12 Cr | 0.00 | |
| Mar2019 | ₹12 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -18.91 % |
| 5 Yr CAGR | 1.62 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 10.46 % | -18.91 | |
| Mar2022 | 12.9 % | 19.89 | |
| Mar2021 | 10.76 % | 1.61 | |
| Mar2020 | 10.59 % | 7.95 | |
| Mar2019 | 9.81 % | - | |
MEDICAMEN BIOTECH Earnings Per Share (EPS)
[BOM: 531146|NSE : MEDICAMEQ]
| Y-o-Y | -4.51 % |
| 5 Yr CAGR | 3.15 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹12 | -4.51 | |
| Mar2022 | ₹12 | 22.76 | |
| Mar2021 | ₹9.93 | -8.73 | |
| Mar2020 | ₹11 | 5.84 | |
| Mar2019 | ₹10 | - | |
MEDICAMEN BIOTECH Return on Capital Employed (ROCE)
[BOM: 531146|NSE : MEDICAMEQ]
| Y-o-Y | -16.07 % |
| 5 Yr CAGR | -13.39 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 10.86% | -16.07 | |
| Mar2022 | 12.94% | -0.38 | |
| Mar2021 | 12.99% | -21.46 | |
| Mar2020 | 16.54% | -14.30 | |
| Mar2019 | 19.3% | - | |
MEDICAMEN BIOTECH Share Price vs Sensex
| Current Share Price | : | ₹416.8 |
| Current MarketCap | : | ₹ 529.3 Cr |
| Updated EOD on | : | Apr 19,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MEDICAMEN BIOTECH | 1.7% |
-21.3% |
-34% |
| SENSEX | -2.6% |
-0% |
21% |
MEDICAMEN BIOTECH related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE SMALL CAP | -1.6% | 8.4% | 61.4% |
| S&P BSE MIDSMALLCAP | -2.1% | 6.3% | 61.6% |
| S&P BSE ALLCAP | -2.5% | 2.7% | 37.3% |
| S&P BSE HEALTHCARE | -3.6% | 0.7% | 51.1% |
No NSE index found
You may also like the below Video Courses
FAQ about MEDICAMEN BIOTECH Financials
How the annual revenues of MEDICAMEN BIOTECH have changed ?
The Revenues of MEDICAMEN BIOTECH have decreased by -100.00% YoY .
How the Earnings per Share (EPS) of MEDICAMEN BIOTECH have changed?
The Earnings Per Share (EPS) of MEDICAMEN BIOTECH has decreased by -4.51 % YoY .
Check out Intrinsic Value of Peers of MEDICAMEN BIOTECH
Compare Stock Analytics of Peers of MEDICAMEN BIOTECH
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
